Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000321942 | SCV000333931 | pathogenic | not provided | 2015-08-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001228238 | SCV001400628 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2; Autosomal recessive limb-girdle muscular dystrophy type 2N | 2023-06-22 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr376Profs*23) in the POMT2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POMT2 are known to be pathogenic (PMID: 15894594). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with clinical features of muscular dystrophy-dystroglycanopathy (PMID: 22323514). This variant is also known as c.1124insAC. ClinVar contains an entry for this variant (Variation ID: 282447). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV001228238 | SCV005635514 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2; Autosomal recessive limb-girdle muscular dystrophy type 2N | 2024-04-16 | criteria provided, single submitter | clinical testing |